Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ib-Meca SCHEMBL12265127 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29572081 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29634441 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL465039 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL10089200 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29384499 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL10089244 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL8922766 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL20905217 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4MAPK1ADORA2A | |
| Ib-Meca SCHEMBL29762168 | 0.94 | ADORA3 (0.89) | ADORA3ADORA1CYP3A4MAPK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | CAN-FITE BIOPHARMA LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| EP-3530273-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF A SEXUAL DYSFUNCTION | CAN FITE BIOPHARMA LTD (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | disclosed |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2020-12-10 | — | — | US | disclosed |
| EP-3380104-B1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN FITE BIOPHARMA LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2020-09-22 | — | — | US | disclosed |
| EP-3530273-A2 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Can-Fite Biopharma Ltd. (IL) | 2019-08-28 | — | — | EP | disclosed |
| US-20180264022-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2018-09-20 | — | — | US | disclosed |
| US-9549943-B2 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | CAN-FITE BIOPHARMA LTD. (IL) | 2017-01-24 | — | — | US | disclosed |
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | disclosed |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | CAN-FITE BIOPHARMA LTD. (IL) | 2010-09-02 | — | — | US | disclosed |
| EP-1976494-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | Can-Fite Biopharma Ltd. (IL) | 2008-10-08 | — | — | EP | disclosed |
| EP-1817079-B1 | TREATMENT OF INFLAMMATION | CAN FITE BIOPHARMA LTD (IL) | 2008-07-30 | — | — | EP | disclosed |
| US-20080051365-A1 | Treatment of Inflammation | CAN-FITE BIOPHARMA LTD. (IL) | 2008-02-28 | — | — | US | disclosed |
| US-20080051364-A1 | Therapeutic Treatment of Accelerated Bone Resorption | CAN-FITE BIOPHARMA LTD. (IL) | 2008-02-28 | — | — | US | disclosed |
| EP-1817079-A1 | TREATMENT OF INFLAMMATION | Can-Fite Biopharma Ltd. (IL) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007086044-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | CAN-FITE BIOPHARMA LTD. (IL) | 2007-08-02 | — | — | WO | disclosed |
| US-20070099865-A1 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| WO-2006059328-A1 | TREATMENT OF INFLAMMATION | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA3 12/4885ADORA1 18/4885CYP3A4 3209/4885 |
| US-20070099865-A1 | Treatment of dry eye conditions | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885ADORA1 5/4885CYP3A4 2668/4885 |
| US-20180264022-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, ADORA3 | ADORA3 3/4885ADORA1 10/4885CYP3A4 3276/4885 |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | ADORA3 2/4885ADORA1 4/4885CYP3A4 4006/4885 |
| US-20200384009-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | GPR119, ADORA2A, FABP4 | ADORA3 5/4885ADORA1 11/4885CYP3A4 2980/4885 |
| US-20100222369-A1 | TREATMENT FOR DRY EYE CONDITIONS | ADORA3, ADORA2A, ADORA2B | ADORA3 1/4885ADORA1 4/4885CYP3A4 2982/4885 |
| US-20080051364-A1 | Therapeutic Treatment of Accelerated Bone Resorption | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA1 2/4885CYP3A4 1186/4885 |
| US-20080051365-A1 | Treatment of Inflammation | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885CYP3A4 1195/4885 |
| US-10780106-B2 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | GPR119, FABP1, INSR | ADORA3 13/4885ADORA1 22/4885CYP3A4 3500/4885 |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | ADORA3, ADORA2A, FABP4 | ADORA3 1/4885ADORA1 4/4885CYP3A4 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.